Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

monoclonal antibody 2021

Known as: concizumab, mAb 2021 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Results from the main parts (24 weeks) of two concizumab phase 2 trials are presented: explorer4 (NCT03196284) in hemophilia A… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2019
2019
INTRODUCTION Concizumab enhances thrombin generation (TG) potential in haemophilia patients by inhibiting tissue factor pathway… Expand
Is this relevant?
2018
2018
Essentials explorer™3 was a double-blinded, multiple-dose escalation trial of subcutaneous concizumab. A pharmacodynamic… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2017
2017
AIMS Concizumab, a humanized monoclonal antibody against tissue factor pathway inhibitor (TFPI), is being developed as a… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2017
2017
Although great strides have been made forward in the last three decades in the treatment of haemophilia A, approximately one in… Expand
Is this relevant?
2016
2016
The development of inhibitors to factor VIII (FVIII) or factor IX (FIX) remains a major treatment complication encountered in the… Expand
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Prophylaxis with either intravenous (i.v.) factor VIII (FVIII) or FIX is the gold standard of care for patients with… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2014
2014
INTRODUCTION Concizumab (mAb 2021) is a monoclonal IgG4 antibody (mAb) that binds to the Kunitz-type protease inhibitor (KPI) 2… Expand
Is this relevant?
2014
2014
INTRODUCTION A humanised monoclonal antibody, concizumab, that binds with high affinity to the Kunitz-type protease inhibitor… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?